fda warning compounding semaglutide september 2025 Sends Letters to More Than 50 GLP-1 Compounders and Manufacturers FDA Targets GLP-1 and Peptide

They discovered that both patient groups exhibited signs of elevated oxidative stress

Drug delivery of gelatin nanoparticles as a biodegradable polymer for the treatment of infectious diseases: perspectives and challenges

Distinguishing between expected adjustment reactions and concerning psychiatric symptoms is essential for patient safety

Gastrointestinal side effects are more common but typically mild and often resolve with dose titration or adjustment

Regulatory bodies should consider targeted enforcement against false advertising and implement clearer labeling and import restrictions for products containing synthetic melanocortin analogs

PlexusDx has no commercial relationship with the manufacturers reviewed